183 related articles for article (PubMed ID: 30138550)
1. Distinct Clinical and Pathological Features of Melorheostosis Associated With Somatic MAP2K1 Mutations.
Jha S; Fratzl-Zelman N; Roschger P; Papadakis GZ; Cowen EW; Kang H; Lehky TJ; Alter K; Deng Z; Ivovic A; Flynn L; Reynolds JC; Dasgupta A; Miettinen M; Lange E; Katz J; Klaushofer K; Marini JC; Siegel RM; Bhattacharyya T
J Bone Miner Res; 2019 Jan; 34(1):145-156. PubMed ID: 30138550
[TBL] [Abstract][Full Text] [Related]
2. Melorheostotic Bone Lesions Caused by Somatic Mutations in MAP2K1 Have Deteriorated Microarchitecture and Periosteal Reaction.
Fratzl-Zelman N; Roschger P; Kang H; Jha S; Roschger A; Blouin S; Deng Z; Cabral WA; Ivovic A; Katz J; Siegel RM; Klaushofer K; Fratzl P; Bhattacharyya T; Marini JC
J Bone Miner Res; 2019 May; 34(5):883-895. PubMed ID: 30667555
[TBL] [Abstract][Full Text] [Related]
3. Somatic activating mutations in MAP2K1 cause melorheostosis.
Kang H; Jha S; Deng Z; Fratzl-Zelman N; Cabral WA; Ivovic A; Meylan F; Hanson EP; Lange E; Katz J; Roschger P; Klaushofer K; Cowen EW; Siegel RM; Marini JC; Bhattacharyya T
Nat Commun; 2018 Apr; 9(1):1390. PubMed ID: 29643386
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics of 10 Chinese patients with melorheostosis and identification of a somatic MAP2K1 variant in one case.
Han X; Xu Y; Wei Z; Wang C; Yue H; Zhang Z
Mol Genet Genomic Med; 2022 Oct; 10(10):e2043. PubMed ID: 36004822
[TBL] [Abstract][Full Text] [Related]
5. Somatic SMAD3-activating mutations cause melorheostosis by up-regulating the TGF-β/SMAD pathway.
Kang H; Jha S; Ivovic A; Fratzl-Zelman N; Deng Z; Mitra A; Cabral WA; Hanson EP; Lange E; Cowen EW; Katz J; Roschger P; Klaushofer K; Dale RK; Siegel RM; Bhattacharyya T; Marini JC
J Exp Med; 2020 May; 217(5):. PubMed ID: 32232430
[TBL] [Abstract][Full Text] [Related]
6. Melorheostosis and Osteopoikilosis: A Review of Clinical Features and Pathogenesis.
Wordsworth P; Chan M
Calcif Tissue Int; 2019 May; 104(5):530-543. PubMed ID: 30989250
[TBL] [Abstract][Full Text] [Related]
7. A multi-omics approach expands the mutational spectrum of MAP2K1-related melorheostosis.
De Ridder R; Boudin E; Zillikens MC; Ibrahim J; van der Eerden BCJ; Van Hul W; Mortier G
Bone; 2020 Aug; 137():115406. PubMed ID: 32387835
[TBL] [Abstract][Full Text] [Related]
8. VEGF Secretion Drives Bone Formation in Classical MAP2K1+ Melorheostosis.
Allbritton-King JD; Maity J; Patel A; Colbert RA; Navid F; Bhattacharyya T
J Bone Miner Res; 2023 Dec; 38(12):1834-1845. PubMed ID: 37737377
[TBL] [Abstract][Full Text] [Related]
9. Distribution and Functional Consequences of Somatic MAP2K1 Variants in Affected Skin Associated with Bone Lesions in Melorheostosis.
Jha S; Ivovic A; Kang H; Meylan F; Hanson EP; Rimland C; Lange E; Katz J; McBride A; Warner AC; Edmondson EF; Cowen EW; Marini JC; Siegel RM; Bhattacharyya T
J Invest Dermatol; 2021 Mar; 141(3):688-692.e11. PubMed ID: 32791068
[No Abstract] [Full Text] [Related]
10. Melorheostosis: a Rare Sclerosing Bone Dysplasia.
Kotwal A; Clarke BL
Curr Osteoporos Rep; 2017 Aug; 15(4):335-342. PubMed ID: 28676968
[TBL] [Abstract][Full Text] [Related]
11. CT analysis of anatomical distribution of melorheostosis challenges the sclerotome hypothesis.
Jha S; Laucis N; Kim L; Malayeri A; Dasgupta A; Papadakis GZ; Karantanas A; Torres M; Bhattacharyya T
Bone; 2018 Dec; 117():31-36. PubMed ID: 30218789
[TBL] [Abstract][Full Text] [Related]
12. Melorheostosis: A Clinical, Pathologic, and Radiologic Case Series.
Fick CN; Fratzl-Zelman N; Roschger P; Klaushofer K; Jha S; Marini JC; Bhattacharyya T
Am J Surg Pathol; 2019 Nov; 43(11):1554-1559. PubMed ID: 31386640
[TBL] [Abstract][Full Text] [Related]
13. Melorheostosis and Osteopoikilosis Clinical and Molecular Description of an Italian Case Series.
Gnoli M; Staals EL; Campanacci L; Bedeschi MF; Faletra F; Gallone S; Gaudio A; Mattina T; Gurrieri F; Percesepe A; Neri I; Virdi A; Tremosini M; Milanesi A; Brizola E; Pedrini E; Sangiorgi L
Calcif Tissue Int; 2019 Aug; 105(2):215-221. PubMed ID: 31129707
[TBL] [Abstract][Full Text] [Related]
14. Clinical Evaluation of Melorheostosis in the Context of a Natural History Clinical Study.
Jha S; Cowen EW; Lehky TJ; Alter K; Flynn L; Reynolds JC; Lange E; Katz JD; Marini JC; Siegel RM; Bhattacharyya T
JBMR Plus; 2019 Aug; 3(8):e10214. PubMed ID: 31485554
[TBL] [Abstract][Full Text] [Related]
15. The dripping candle wax sign of melorheostosis.
Hoang VT; Van HAT; Chansomphou V; Trinh CT
SAGE Open Med Case Rep; 2020; 8():2050313X20940564. PubMed ID: 32922791
[TBL] [Abstract][Full Text] [Related]
16. Constitutive activation of MEK1 in osteoprogenitors increases strength of bone despite impairing mineralization.
Fowlkes JL; Bunn RC; Ray PD; Kalaitzoglou E; Uppuganti S; Unal M; Nyman JS; Thrailkill KM
Bone; 2020 Jan; 130():115106. PubMed ID: 31689526
[TBL] [Abstract][Full Text] [Related]
17. Bone dysplasia series. Melorheostosis: review and update.
Greenspan A; Azouz EM
Can Assoc Radiol J; 1999 Oct; 50(5):324-30. PubMed ID: 10555508
[TBL] [Abstract][Full Text] [Related]
18. Melorheostosis involving the craniofacial skeleton.
Ethunandan M; Khosla N; Tilley E; Webb A
J Craniofac Surg; 2004 Nov; 15(6):1062-5. PubMed ID: 15547407
[TBL] [Abstract][Full Text] [Related]
19. Cross-Sectional Imaging Useful in Melorheostosis.
Hurley-Novatny A; Karantanas AH; Papadakis GZ; Bhattacharyya T; Jha S
JBMR Plus; 2021 Apr; 5(4):e10472. PubMed ID: 33869990
[TBL] [Abstract][Full Text] [Related]
20. Histopathological characterization of melorheostosis.
Hoshi K; Amizuka N; Kurokawa T; Nakamura K; Shiro R; Ozawa H
Orthopedics; 2001 Mar; 24(3):273-7. PubMed ID: 11300293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
